IP Verse

New Use Of An Anti-Cd303 Transmembrane Protein Antibody - EP3390452

The patent EP3390452 was granted to Laboratoire Franais DU Fractionnement ET DES Biotechnologies on May 26, 2021. The application was originally filed on Dec 16, 2016 under application number EP16826758A. The patent is currently recorded with a legal status of "Revoked".

EP3390452

LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Application Number
EP16826758A
Filing Date
Dec 16, 2016
Status
Revoked
May 5, 2023
Grant Date
May 26, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANFeb 28, 2022VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO0136487
INTERNATIONAL-SEARCH-REPORTWO2009138489
INTERNATIONAL-SEARCH-REPORTWO2012080642
INTERNATIONAL-SEARCH-REPORTWO2015095143
OPPOSITIONWO2012080642
OPPOSITIONWO2014093396
OPPOSITIONWO2015095143
OPPOSITIONWO2016156449
OPPOSITIONWO2016156450
OPPOSITIONWO2017103521

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anandi Sawant, "Role of plasmacytoid dendritic cells in breast cancer bone dissemination", Oncoimmunology, (20130000), vol. 2, no. 2, XP055904314
OPPOSITION- Isabelle Le Mercier et al, "Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment", Cancer Res, (20130000), vol. 73, pages 4629 - 4640, XP055904317
OPPOSITION- Leonardo Boiocchi, Silvia Lonardi, William Vermi, Simona Fisogni And Fabio Facchetti, "BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoiddendritic cells", Blood, (20130711), vol. 122, no. 2, pages 296 - 297, XP055904157
OPPOSITION- Petrella, Et Al, "Tumoral aspects of plasmacytoid dendritic cells: What do we know in 2009?", Autoimmunity, (20100501), vol. 43, no. 3, pages 210 - 214, XP055463392
OPPOSITION- PILONES, "Combination of Radiotherapy and Immune Checkpoint Inhibitors", Semin Radiat Oncol, (20150000), vol. 25, pages 28 - 33, XP055904168
OPPOSITION- Rosalinda Sorrentino et al, "Plasmacytoid Dendritic Cells Alter the Antitumor Activity of CpG-Oligodeoxynucleotides in a MouseModel of Lung Carcinoma", the journal of Immunology, (20100000), vol. 185, pages 4641 - 4650, XP055904320
OPPOSITION- SAWANT, "Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells", The Journal of Immunology, (20120000), vol. 189, pages 4258 - 4265, XP055904315
OPPOSITION- Stephanie Demoulin et al, "Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms", J Leukoc Biol, (20130000), vol. 93, pages 343 - 352, XP055904312
OPPOSITION- William Vermi et al, "Plasmacytoid dendritic cells and cancer", journal of Leukocyte Biology, (20110000), vol. 90, pages 681 - 690, XP055904313
OPPOSITION- E. Arduin, S. Arora, P.R. Bamert, T. Kuiper, S. Popp, S. Geisse, R. Grau, T. Calzascia, G. Zenke, J. Kovarik, "Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a", MOLECULAR IMMUNOLOGY, PERGAMON, GB, GB , (20150201), vol. 63, no. 2, doi:10.1016/j.molimm.2014.09.017, ISSN 0161-5890, pages 456 - 463, XP055499655
OPPOSITION- VAFA OMID, ET AL, "An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.", Methods, Academic Press, NL, NL , (20140101), vol. 65, no. 1, doi:10.1016/J.YMETH.2013.06.035, ISSN 1046-2023, pages 114 - 126, XP002738919
OPPOSITION- Swiecki Melissa, Colonna Marco, "The multifaceted biology of plasmacytoid dendritic cells", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20150801), vol. 15, no. 8, doi:10.1038/nri3865, ISSN 1474-1733, pages 471 - 485, XP055876477
OPPOSITION- DZIONEK A, ET AL, "BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20011217), vol. 194, no. 12, doi:10.1084/jem.194.12.1823, ISSN 0022-1007, pages 1823 - 1834, XP002277387
OPPOSITION- Melissa Swiecki, Colonna Marco, "Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20100301), vol. 234, no. 1, doi:10.1111/j.0105-2896.2009.00881.x, ISSN 0105-2896, pages 142 - 162, XP055352056
OPPOSITION- Maeda Takahiro; Murata Kenn; Fukushima Takuya; Sugahara Kazuyuki; Tsuruda Kazuto; Anami Masanobu; Onimaru Yasuyuki; Tsukasaki Kunihiro; Tomonaga Masao; Moriuchi Ryouzou; Hasegawa Hiroo; Yamada Yasuaki; Kamihira Shimeru, "A Novel Plasmacytoid Dendritic Cell Line, CAL-1, Established from a Patient with Blastic Natural Killer Cell Lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY., ELSEVIER SCIENCE PUBLISHERS., NL, NL , (20050201), vol. 81, no. 2, doi:10.1532/IJH97.04116, ISSN 0925-5710, pages 148 - 154, XP036522530

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents